NovoCure shares are trading lower after the company announced its Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 trial of TTFields with paclitaxel did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
NovoCure announced that its Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 trial of TTFields with paclitaxel did not meet its primary endpoint, causing its shares to trade lower.
August 28, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NovoCure's shares are trading lower after the company's Phase 3 trial did not meet its primary endpoint.
The failure of a Phase 3 trial is a significant setback for any pharmaceutical company, as it indicates that the drug may not be as effective as previously thought. This can lead to a decrease in investor confidence, resulting in a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100